Insider Buying: Oncolytics Biotech (NASDAQ:ONCY) CFO Acquires $10,080.00 in Stock

Oncolytics Biotech Inc. (NASDAQ:ONCY) CFO Kirk Look acquired 12,000 shares of Oncolytics Biotech stock in a transaction that occurred on Thursday, February 12th. The stock was acquired at an average cost of $0.84 per share, for a total transaction of $10,080.00. Following the purchase, the chief financial officer owned 287,515 shares of the company’s stock, valued at $241,512.60. The trade was a 4.36% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Oncolytics Biotech Stock Up 27.0%

Shares of NASDAQ:ONCY opened at $1.06 on Monday. The firm has a market cap of $112.52 million, a P/E ratio of -3.79 and a beta of 0.99. Oncolytics Biotech Inc. has a 12-month low of $0.33 and a 12-month high of $1.51. The business has a fifty day simple moving average of $0.98 and a 200 day simple moving average of $1.07.

Hedge Funds Weigh In On Oncolytics Biotech

Institutional investors have recently added to or reduced their stakes in the business. Scientech Research LLC bought a new position in shares of Oncolytics Biotech during the 3rd quarter worth approximately $25,000. Security National Bank of Sioux City Iowa IA acquired a new position in shares of Oncolytics Biotech during the 4th quarter valued at $29,000. Ground Swell Capital LLC acquired a new position in shares of Oncolytics Biotech during the 4th quarter valued at $30,000. CIBC Private Wealth Group LLC acquired a new stake in Oncolytics Biotech in the fourth quarter worth $44,000. Finally, Tocqueville Asset Management L.P. bought a new stake in Oncolytics Biotech in the fourth quarter valued at $63,000. 6.82% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Oncolytics Biotech

Here are the key news stories impacting Oncolytics Biotech this week:

• Positive Sentiment: Director Patricia S. Andrews bought 35,400 shares at $0.86 (raising her stake 82.85% to 78,128 shares). SEC Filing
• Positive Sentiment: Insider Andrew Aromando purchased 29,600 shares at $0.86 (increasing his position 116.08% to 55,100 shares). SEC Filing
• Positive Sentiment: Director Bernd R. Seizinger acquired a total of 100,000 shares across Feb. 11–12 (60k at $0.83 and 40k at $0.85), boosting his holdings to ~566,991 shares. SEC Filing
• Positive Sentiment: VP Allison Hagerman bought 10,000 shares at $0.83 (raising her stake ~9.5% to 115,059 shares). SEC Filing
• Positive Sentiment: Director Deborah M. Brown purchased 25,000 shares at $0.85 (a ~29.5% increase; now ~109,851 shares). SEC Filing
• Positive Sentiment: Insider Thomas C. Heineman bought 12,132 shares at $0.83 (increasing to ~282,818 shares). SEC Filing
• Positive Sentiment: Director Wayne Pisano purchased 30,000 shares at $0.84 (raising his stake ~6.5% to ~492,414 shares). SEC Filing
• Positive Sentiment: CFO Kirk Look bought 12,000 shares at $0.84 (increasing to ~287,515 shares). SEC Filing
• Positive Sentiment: CEO Jared Kelly purchased a total of 35,100 shares across Feb. 11–12 at ~$0.84 (bringing his holdings to ~109,000 shares, a ~37% increase). SEC Filing

Analyst Ratings Changes

A number of research firms recently commented on ONCY. Wall Street Zen lowered Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. HC Wainwright boosted their price target on shares of Oncolytics Biotech from $5.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday, November 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Oncolytics Biotech in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $6.25.

About Oncolytics Biotech

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.